LATEST NEWS

January, 2012

iSonea Limited Commences Trading on the U.S. OTCQX International

iSonea Limited Announces Publication of Initial Viriathus Research Report

December, 2011

iSonea receives Subscriptions under Rights Issue...

Shareholders Top 20 Listing

Notice of change of interests of substantial holder (RB)

Appendix 3Y: Change of Director’s Interest Notice (RH)

Notice of ceasing to be a substantial holder

Appendix 3Y: Change of Director’s Interest Notice (JK)

Notice Under Section 708A(5) of the Corporations Act

Appendix 3B: New Issue Announcement, Application for Quotation of Additional Securities and Agreement

Dispatch of Renounceable Pro-Rata Rights Issue Closure, Acceptances, Shortfall

Michael Thomas, iSonea CEO talks with BRR on launch of new iPhone Application

Rights Issue Prospectus Announcement

 

PUBLICATIONS

Articles for Health Professionals

         Prof. Simon Godfrey, MD, PhD, FRCP, FRCPCH

Parthak Prodhan MD, Reynaldo S Dela Rosa MD, Maria Shubina MSc, Kenan E Haver MD,Benjamin D Matthews MD, Sarah Buck RN, Robert M Kacmarek RRT PhD FAARC, and Natan N Noviski MD

RESPIRATORY CARE, OCTOBER 2008 VOL 53 NO 10

 

© 2011 iSonea (formerly Karmelsonix) Ltd| Disclaimer, Terms and Conditions, Copyright and Intellectual Property.

BlackFin Processor
BlackFin® Processor
KarmelSonix ISO Certification
iSonea
ISO Certification 2003
US Food & Drug Administration

US Food & Drug Administration
Australian Government

Australian Government
Therapeutic Goods Administration


CE Certification

CE Certification